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Liposome-based vaccines
Abstract
Here, we report methods of preparation of liposome vaccine formulations for the entrapment of
antigenic peptides and antigen encoding plasmid DNAs. Two examples of liposomal vaccine
formulations producing highly effective immune responses are given. Firstly, a formulation with
encapsulated antigenic peptides derived from the hepatitis C virus NS4 and the core proteins, and
secondly, the encapsulation of a plasmid DNA encoding the gp33 glycoprotein of the lymphocytic
choriomeningitis virus (LCMV). Vaccination with liposomal HCV peptides in HLA-A2 transgenic mice
by subcutaneous injections induced strong cytotoxic T cell responses as shown by lysis of human target
cells expressing HCV proteins. The immunogenicity of the liposomal peptide vaccines was further
enhanced by incorporation of immunostimulatory CpG oligonucleotide sequences, shown by a strong
increase of the frequency of IFN-gamma secreting cells that persisted at high levels for long periods of
time. With the LCMV model, we could show that upon intradermal injection, plasmid-DNA liposomes
formed LCMV gp33 antigen depots facilitating long-lasting in vivo antigen loading of dendritic cells
(DC), followed by a strong immune response. Our data show that liposomal formulations of peptide or
plasmid-DNA vaccines are highly effective at direct in vivo antigen loading and activation of DC
leading to protective antiviral and anti-tumor immune responses.
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Liposome-Based Vaccines
Reto A. Schwendener, Burkhard Ludewig, Andreas Cerny,  
and Olivier Engler
Abstract 
Here, we report methods of preparation of liposome vaccine formulations for the entrapment of antigenic 
peptides and antigen encoding plasmid DNAs. Two examples of liposomal vaccine formulations producing 
highly effective immune responses are given. Firstly, a formulation with encapsulated antigenic peptides 
derived from the hepatitis C virus NS4 and the core proteins, and secondly, the encapsulation of a plasmid 
DNA encoding the gp33 glycoprotein of the lymphocytic choriomeningitis virus (LCMV). Vaccination 
with liposomal HCV peptides in HLA-A2 transgenic mice by subcutaneous injections induced strong 
cytotoxic T cell responses as shown by lysis of human target cells expressing HCV proteins. The immuno-
genicity of the liposomal peptide vaccines was further enhanced by incorporation of immunostimulatory 
CpG oligonucleotide sequences, shown by a strong increase of the frequency of IFN-g secreting cells that 
persisted at high levels for long periods of time. With the LCMV model, we could show that upon intrad-
ermal injection, plasmid–DNA liposomes formed LCMV gp33 antigen depots facilitating long-lasting 
in vivo antigen loading of dendritic cells (DC), followed by a strong immune response. Our data show that 
liposomal formulations of peptide or plasmid–DNA vaccines are highly effective at direct in vivo antigen 
loading and activation of DC leading to protective antiviral and anti-tumor immune responses.
Key words: Liposomes, Peptides, DNA, Immunostimulatory oligonucleotides, CpG, Immunization, 
Dendritic cells, Adjuvants, Vaccines, HCV, LCMV
With the availability of well-characterized antigens, in particular 
with highly purified proteins or synthetic peptides, more effective 
and safer vaccines can be developed. However, this approach may 
be hampered by the fact that many antigens are often poorly 
immunogenic when administered alone, necessitating the devel-
opment of suitable adjuvants that have the ability to potentiate 
the immunogenic effect of a given antigen, preferably with little 
1.  Introduction
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or no side effects. Adjuvants can be divided into two groups, 
based on their principal mechanisms of action: (1) vaccine delivery 
systems (1–5) and (2) immunostimulatory adjuvants (6, 7). 
Vaccine delivery systems are generally composed of particles of 
comparable dimensions to pathogens as bacteria and viruses 
(e.g. liposomes, microemulsions, immunostimulatory complexes 
and other nano- or microparticle systems) (8–11).
These systems function mainly to target associated antigens 
to antigen-presenting cells (APC). Currently, complex formula-
tions are being developed in which carrier systems are exploited 
both for the delivery of antigens and of co-administered immu-
nostimulatory adjuvants either to isolated APCs (macrophages, 
dendritic cells) or by direct in vivo applications (12–14). Such 
approaches are used to ensure that both antigen and adjuvant 
are delivered to the same population of APCs. Additionally, par-
ticulate delivery systems can specifically target the adjuvant 
effect to the key cells of the immune system, reducing systemic 
distribution and minimizing induction of adverse reactions. 
Small unilamellar liposomes have a significant potential as deliv-
ery systems for the co-administration of antigens (peptides, 
lipopeptides) and of immunostimulatory adjuvants, including 
CpG oligonucleotides or DNA encoding antigens and/or 
immunostimulatory sequences (15). Additionally, the efficacy of 
liposome-based vaccines can be improved by targeting them 
more effectively and specifically to the APCs by exploiting vari-
ous scavenger and other receptors as their targets (16–18) or by 
enhancing their cell uptake properties by modification with cell 
penetrating peptides (19).
Here, we present methods of preparation of liposomal 
vaccines and results obtained in our laboratories with small uni-
lamellar liposomes as carriers of antigen peptides and peptide 
encoding DNA plasmids, demonstrating their high potential 
as therapeutic vaccine formulations against infectious diseases 
and cancers.
 1. Soy phosphatidylcholine (SPC) (L. Meyer GmbH, Hamburg, 
Germany), store at −20°C, prepare a stock solution, e.g. of 
20–100 mg/mL by dissolving SPC in methanol/methylene 
chloride (1:1, v/v).
 2. Cholesterol (see Note 1).
 3. D,L-a-Tocopherol (Merck, Darmstadt, Germany), store at 
−20°C, make a stock solution, e.g. of 10 mg/mL by dissolving 
D,L-a-tocopherol in methanol/methylene chloride (1:1, v/v).
2.  Materials
2.1. Liposome 
Preparation
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 4. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
(Avanti Polar Lipids, Alabaster, AL). Store at −20°C. Make a 
stock solution as described for SPC.
 5. Didodecyldimethyl ammoniumbromide (DDAB) (Fluka, 
Buchs, Switzerland). Store at 4°C.
 6. Phosphate buffer, PB: 13 mM KH2PO4, 54 mM NaHPO4, 
pH 7.4 (see Note 2).
 7. Round bottom flasks (20–100 mL).
 8. Rotatory evaporator, e.g. Rotavap (Buechi AG, Flawil, 
Switzerland).
 9. LipexTM high pression extruder (Northern Lipids Inc., 8855 
Northbrook Court, Burnaby, BC, Canada).
 10. Nuclepore membranes of defined pore sizes: 400; 200; 
100 nm (Sterlitech Corp., Kent, WA, USA or Sterico AG, 
Wangen, Switzerland).
 11. BSS, balanced salt solution.
 12. TE buffer: 10 mM Tris–HCl, pH 8, 10 mM EDTA.
 13. Sterile filters, 0.45 or 0.2 mm and plastic syringes, various 
suppliers.
 1. The HLA-A2 restricted CD8+ T cell epitope peptide from the 
Hepatitis C virus core protein c132 (aa 132–140; DLMGYIPLV; 
>95% purity) and the peptide NS1851 from the NS4 protein 
(aa 1851–1859; ILAGYGAGV; >95% purity) were from 
Neosystems (Strasbourg, France) and stored at 4°C.
 2. The immunostimulatory oligonucleotide ODN1668 
(5¢-TCCATGACG-TTCCTGATGCT-3¢), referred to as CpG 
was synthesized by Microsynth (Balgach, Switzerland) and 
stored at −20°C.
 3. The plasmid pEGFPL-33A was kindly provided by Stefan 
Oehen (20). This vector is composed of a DNA insert coding 
for a FLAG Tag (DYKDDDDK) and the gp33 epitope 
(KAVYNFATM) flanked N-terminally by three leucines and 
C-terminally by four alanines inserted in the pEGFP-N3 
expression vector (Clontech, Palo Alto, CA). The gp33 
peptide is the immunodominant epitope of the lymphocytic 
choriomeningitis virus glycoprotein.
 1. DNase I (RNase free) (Roche Diagnostics, Rotkreuz, 
Switzerland).
 2. Magnesium chloride (MgCl2) and EDTA.
 3. Biogel A-15 (10 × 1 cm) column (Bio-Rad Laboratories) or 
corresponding product.
 4. Phosphorus-32 (Amersham Biosciences, Amersham, UK).
2.2. Peptides, Plasmids 
and Adjuvants
2.3.  Enzymatic Digestion 
of Non-entrapped 
Plasmid DNA  
and Determination  
of Encapsulated 
Plasmid DNA
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The methods described in the following section outline (1) the 
preparation of liposomes by high pressure filter extrusion, 
(2) the encapsulation of peptide antigens and immunostimula-
tory CpG oligonucleotides and (3) the preparation of plasmid 
DNA liposomes encoding the LCMV GP33 peptide antigen.
We do not describe in details the immunological methods 
(immunization, 51Cr release assay, ELISPOT, ELISA and flow 
cytometry) used for the analysis of the immune responses induced 
by the liposome vaccines (Subheading 3.2). For comprehensive 
information, we refer to our publications (21–23) and to the 
related literature.
Liposomes belong to the most studied particulate carrier systems. 
In the past decades, a vast number of liposome preparation methods 
for the encapsulation of a large variety of molecules have been 
developed and refined. We refer to the corresponding literature 
and to our publications for more information. We recommend the 
high pressure filter extrusion method for the preparation of peptide or 
DNA containing liposomes because of its ease, versatility, up-scaling 
options and high quality of the liposomes produced.
Liposomes can be composed of a large selection of phospholipids 
and additional lipophilic compounds like cholesterol, poly(ethylene 
glycol) lipids (PEG), glycolipids, and antioxydants. Depending 
on the intended application, different lipid compositions have to 
be selected. The “state-of-the-art” liposomes used for intrave-
nous applications, e.g. liposomes carrying cytotoxic antitumor 
drugs, are those composed of lipids containing hydrophilic carbo-
hydrates or polymers, mainly poly(ethylene glycol) modified 
phospholipids. Such PEG- or “stealth” liposomes evade fast 
absorption in the mononuclear phagocyte system and have long 
blood circulating times (24). Liposome formulations carrying 
antigens intended as vaccines are administered by subcutaneous 
or intradermal injection and usually do not require further 
modifications, since the targets are phagocytosing cells such as 
macrophages and dendritic cells that are mainly localized at the 
site of injection. Their composition can be kept quite simple by 
choosing phospholipids (SPC, synthetic phospholipids) and 
cholesterol as main components. Nevertheless, they may be modi-
fied by specific molecules (e.g. mannosylated lipids) that recog-
nize and bind to receptors expressed on APCs (17). Another 
important feature facilitating broad applications and up-scaling of 
the preparations is that antigen and DNA containing liposomes 
can be formulated as stable lyophilized products by addition of 
appropriate cryoprotectants (25).
3.  Methods
3.1. Liposome 
Preparation
3.1.1. Liposome 
Compositions
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Peptide liposome vaccines were prepared by freeze–thawing 
of the lipid/peptide mixtures followed by sequential filter 
extrusion.
 1. The basic composition for the preparation of 5.0 mL lipo-
somes was 1.0 g soy phosphatidylcholine (SPC, L. Meyer 
GmbH, Hamburg, Germany), 125 mg cholesterol (Fluka, 
Buchs, Switzerland) (see Note 1) and 6 mg D,L-a-tocopherol 
(Merck, Darmstadt, Germany) as antioxidant.
 2. The solid lipids were dissolved in methanol/methylene chlo-
ride (1:1, v/v) in a round bottom flask or corresponding 
amounts of stock solutions were added.
 3. After removal of the organic solvents by rotary evaporation 
(40–45°C, 30–60 min), the dry lipid mixture was solubilized 
with the HCV c132 or NS4 1851 peptide (4 mg/mL) dis-
solved in phosphate buffer PB (67 mM, pH 7.4) by vigorous 
agitation (see Notes 2 and 3). In addition to the peptide 
antigens, some formulations contained immunostimulatory 
CpG oligonucleotides (250 nmol/mL in Tris/EDTA buffer) 
which were added likewise to the lipids.
 4. The mixture was then subjected to 3–5 freeze–thaw cycles 
(liquid nitrogen–water 40°C; see Note 4), followed by repet-
itive extrusion through Nuclepore (Sterlitech Corp., Kent, 
WA, USA or Sterico AG, Wangen, Switzerland) filters (800, 
400 and 200 nm pore size) using a Lipex™ Extruder 
(Northern Lipids Inc.) (see Note 5).
 5. Liposomes were filter sterilized (0.45- or 0.2-mm sterile filters) 
and diluted in BSS (balanced salt solution). Peptide encapsu-
lation was estimated to range between 80 and 90% according 
to previous determinations (22). Non-entrapped peptides 
and CpG oligonucleotides can either be kept in the prepara-
tion or removed by dialysis.
For example, the preparation of 5 mL liposomes containing 
1.5 mg/mL pEGFPL-33A plasmid encoding the LCMV gp33 
peptide and the green fluorescent protein EGFP is given.
 1. The lipids (456 mg 1-palmitoyl-2-oleyl-sn-glycero-3- 
phosphocholine, POPC and 5.6 mg didodecyldimethyl-
ammoniumbromide, DDAB) in a 20-mL round bottom flask 
were dissolved in an appropriate amount of methylene chlo-
ride/methanol (1:1, v/v, ~20 mL).
 2. The organic solvent was removed by rotary evaporation (40–
45°C, 30–60 min). The plasmid DNA solution (1.5 mg/mL 
in Tris/EDTA buffer) was added to the dry lipid film and the 
lipids solubilized by vigorous agitation (see Note 3).
 3. Then the mixture was subjected to 3–5 freeze–thaw cycles 
followed by filter extrusion as described in Subheading 
3.1.2, step 1.
3.1.2. Liposome 
Preparation by High 
Pressure Filter Extrusion
Preparation  
of Liposomes Containing 
Antigenic HCV Peptides 
and Immunostimulatory 
CpG Oligonucleotides (21)
Preparation  
of Liposomes Containing  
a Peptide-Encoding Plasmid
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 4. Finally, the liposomes were filter sterilized (0.45- or 0.2-mm 
sterile filters) and diluted in BSS.
Non-entrapped plasmid–DNA was removed by enzymatic digestion, 
followed by separation of liposomes and digested plasmid–DNA 
by column chromatography.
 1. DNase I (80 U/mg) and magnesium chloride (5 mM) were 
added to 1 mL of the DNA-liposomes.
 2. This mixture was incubated for 3 h at 37°C and the reaction 
stopped with EDTA (7 mM).
 3. The digested non-encapsulated DNA was separated from the 
liposomes by gel chromatography on a Biogel A-15 column 
(10 × 1 cm) equilibrated with Tris buffer (50 mM). Separation 
was achieved by elution with Tris buffer (10 mM) and collec-
tion of 0.5–1.0 mL fractions. The plasmid–DNA liposomes 
were eluted in fractions 2–5, whereas digested plasmid DNA 
was retained in the column.
 4. To determine the fraction of encapsulated plasmid–DNA, 
the plasmid was radioactively labeled with 32P (see Note 6). 
Plasmid labeling was done according to conventional meth-
ods in trace amounts before encapsulation into liposomes. 
The percentage of encapsulated plasmid–DNA was deter-
mined after separation from digested non-encapsulated 
DNA. As alternative method, DNA-encapsulation can be 
monitored on agarose gels (0.8%) by application of untreated 
and detergent solubilized liposomes (e.g. Triton X-100 or octyl-
glucoside). Results show that the superhelical conforma-
tion of the plasmid–DNA is preferentially encapsulated in 
the liposomes (not shown).
Six- to eight-week-old HDD mice, transgenic (tg) for HLA-A2.1 
(A0201) major histocompatibility complex (MHC) class I and 
deficient for both H-2Db and murine b2-microglobulin (b2m) 
(26) were immunized with the HLA-A2 restricted CD8+ T cell 
epitope from the Hepatitis C virus NS4 protein NS1851 
(aa 1851–1859; ILAGYGAGV) or from the core protein c132 
(aa 132–140; DLMGYIPLV).
 1. The HLA-2.1 tg mice were injected subcutaneously (s.c.) at 
the base of the tail with 50 mL of the liposome formulation 
(~130 mg peptide) with or without immunostimulatory CpG 
molecules and as control with a saline solution containing the 
peptide (~130 mg peptide). Mice received three injections at a 
2-week interval and the response was analyzed 2 weeks after 
the last injection.
 2. Spleen cells (4 × 106) were isolated to analyze the CTL response 
and restimulated with peptide-pulsed and irradiated spleen cells 
(2 × 106 cells in 2 mL medium). On day 3, IL-2 (2.5 U/mL) was 
 Enzymatic Digestion  
of Non-entrapped Plasmid 
DNA and Determination  
of Encapsulated  
Plasmid DNA
3.2. Immunization with 
Liposomal Antigen 
Formulations
3.2.1. Efficacy of CD8 T 
Cell Induction by 
Liposomes Containing HCV 
Epitopes and Influence  
of an Immunostimulatory 
CpG Oligonucleotide (21)
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added. The specific lysis of peptide pulsed HLA-A2 transfected 
target cells (EL-4S3-Rob HDD) was analyzed in a standard 4 h 
51Cr release assay. Spontaneous and maximal release was deter-
mined from wells containing medium alone or after lysis with 
1N HCl, respectively. Lysis was calculated by the formula:
  % Lysis = (release in assay – spontaneous release)/ 
(maximum release – spontaneous release)´100.
Peptide-specific lysis was determined as the percentage of lysis 
obtained in presence or in absence of the peptide.
 3. For the IFN-g ELISPOT assay splenocytes were re-stimulated 
over night with peptide NS1851 as described for the CTL 
assay. Then, 105 and 104 cells were transferred to precoated 
ELISPOT plates (U-CyTech, Utrecht, Netherlands) and 
incubated for 5 h. Spot formation was analyzed as described 
in the manufacturer’s protocol.
 4. To perform intracellular cytokine staining spleen cells 
(8 × 106 cells in 2 mL medium) were re-stimulated over night 
with 10 mg/mL peptide (c132 or a control peptide). Cells 
were, subsequently treated for 2.5 h with Brefeldin A (Golgy 
Stop, BD Bioscience) and permeabilization/fixation was 
performed with Cytoperm/Cytofix (BD Bioscience) accord-
ing to the manufacturer’s protocol. Surface CD8 was stained 
with anti-mouse CD8a-FITC antibodies (BD Bioscience) 
and IFN-g staining was done with anti-mouse IFN-g-PE 
antibodies or isotype control antibodies (BD Bioscience). 
Fluorescence was analyzed on a Coulter Epics XL-MCL flow 
cytometer (Coulter Corp., Hialeah, FL, USA). The CTL 
responses and IFN-g production are shown in Fig. 1. 
Encapsulation of the peptide NS1851 into liposomes was 
sufficient to induce a specific and strong CTL response 
against peptide-pulsed target cells. No specific cytotoxicity 
was detected in the negative control formulations consisting 
of peptides solubilized in 0.9% NaCl (open circles) or empty 
liposomes (data not shown). Co-administration of immuno-
stimulatory CpG molecules resulted in augmented target cell 
lysis (Fig. 1a).
IFN-g is a potent immunostimulatory and anti-viral cytokine. 
The frequency of specific IFN-g-secreting cells stimulated by lipo-
somal formulations exclusively containing the CTL epitope NS1851 
or combinations with CpG, respectively, was evaluated by ELISPOT 
assay. Two weeks after three immunizations, high numbers of 
specific IFN-g-secreting cells in mice immunized with liposomes 
containing NS1851 (~0.2% of total spleen cells) were detected 
which further increased in mice immunized with liposomal formu-
lations containing CpG (~0.7% of total spleen cells) (Fig. 1b).
The frequency of IFN-g-producing cells was further analyzed 
by intracellular cytokine staining. The results shown in Fig. 2 
Cytotoxic T cell response and IFN- g production after
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Fig. 1. CTL responses (a) and IFN-g production (b) after s.c. injection of NS1851 liposomes (~130 mg peptide; three times 
every 2 weeks) with or without immunostimulatory CpG (250 nmol) or as controls the peptide in saline solution. The CTL 
response was analyzed 2 weeks after the last injection and measured in a standard 51Cr release assay after 5 days of 
re-stimulation in vitro. Black squares represent the response induced by liposomal formulations and open circles  the response 
of the control peptide. IFN-g production was measured by ELISPOT assay after stimulation with peptide pulsed cells
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Fig. 2. Analysis of IFN-g-producing splenocytes by intracellular cytokine staining. Mice were immunized with c132 liposomes 
with or without CpG or with the peptide in 0.9% NaCl. Intracellular IFN-g production was analyzed 14 days after the second 
immunization upon stimulation with the specific peptide c132 or a control peptide. Indicated is a representative example 
of IFN-g producing CD8+ T cells in each vaccine group. IFN-g production of CD8+ T cells derived from control immunized 
mice was always at background levels (0.1%)
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indicate that in mice immunized with liposomes containing 
only the c132 peptide, approximately 1.8% of total splenocytes 
(corresponding to 26% of CD8+ T cells) produced IFN-g in 
response to peptide stimulation, while in mice immunized with 
liposomes containing c132 plus CpG approximately 6.9% of 
splenocytes (corresponding to 49% of CD8+ T cells) produced 
IFN-g upon specific stimulation. IFN-g production of CD8+  
T cells determined from control immunized mice was always at 
background levels (0.1%).
The induction of the LCMV gp33 specific CTL response after 
intradermal immunization with a liposome formulation of 
pEGFPL-33A DNA is shown by specific lysis of re-stimulated 
spleen cells 9 days after the first immunization in Fig. 3.
 1. Three C57BL/6 mice per group were injected intradermally 
with 50 mg of liposomal plasmid DNA (A, C) or 50 mg free 
plasmid DNA (B, D) followed by a second treatment after 
48 h. Three control mice received 50 mg of an antiviral pep-
tide antigen (gp33) in incomplete Freund’s adjuvant (IFA) 
intradermally. Nine days after the first immunization, spleen 
cells were re-stimulated for 5 days and analyzed in a 51Cr-release 
assay on peptide labeled and unlabeled EL-4 cells. The spon-
taneous 51Cr-release was <14% (22).
3.2.2. Induction of a LCMV 
Antigen Specific Immune 
Response with pEGFPL-33A 
Liposomes
Dilution of primary splenocyte culture
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Fig. 3. CTL response after intradermal plasmid vaccination. Three C57BL/6 mice per group were injected intradermally 
with 50 mg of liposomal plasmid DNA (a, c) or 50 mg free plasmid DNA (b). After 48 h the treatment was repeated. As 
control three mice received 50 mg of the antiviral peptide antigen gp33 in IFA. Nine days after the first immunization 
isolated spleen cells were re-stimulated for 5 days and analyzed in a 51Cr-release assay on peptide labeled (filled squares) 
and unlabeled (open squares) EL-4 cells. The spontaneous 51Cr-release was <14%
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The efficiency of the in vivo transfection of APCs after intradermal 
application of liposomal pEGFPL-33A DNA (80 mg) to the left 
flank of C57BL/6 mice was analyzed by flow cytometry.
 1. Regional lymph nodes were removed 36 h after injection. 
The flow cytometric analysis of the crude lymph node cell 
suspension showed that 1.2% of the cells expressed the 
enhanced green fluorescent protein (EGFP) in comparison to 
cells from untreated controls (Fig. 4a).
 2. Dendritic cells were enriched by gradient centrifugation up 
to 50–60% purity. The specific EGFP fluorescence of this 
cell population increased to 5.1% compared to control 
DCs (Fig. 4b).
3.2.3. Detection of EGFP 
Expressing Antigen 
Presenting Cells After 
Intradermal Vaccination 
with pEGFPL-33A DNA 
Liposomes
M1
M11.2% GFP-pos 5.1% GFP-pos
a b
In vivo transfection of dendritic cells with liposomal plasmid-DNA
c d
Fig. 4. Efficiency of in vivo transfection of dendritic cells after intradermal immunization with a liposomal plasmid–DNA 
vaccine. Mice were treated intradermally with 80 mg liposomal plasmid–DNA and after 36 h a sample of the skin at the 
injection site and regional lymph nodes were isolated (Lnn. inguinalis, axillaris, brachialis) and analyzed. (a) Flow 
cytometric analysis of a lymph node cell suspension revealed specific fluorescence in 1.2% of the cells produced by 
the green fluorescent marker protein (EGFP; thick line in a). (b) Dendritic cells were enriched by separation from 
lymph node cells by gradient centrifugation. Specific EGFP-fluorescence in the DC population was 5.1% (thick line in b). 
(c) Immunohistochemical detection of EGFP-positive cells of typical DC morphology (arrow) in the cutaneous tissue 
at the injection site. EGFP expression was visualized by incubation with an anti-EGFP antibody, followed by alkaline 
phosphatase staining. (d) Immunohistochemical detection of EGFP-positive cells in the T-cell area of a regional lymph 
node (Ln. inguinalis; arrows)
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 3. The transfection of APCs with plasmid-liposomes was further 
analyzed by immunohistochemistry. In Fig. 4c, d, expression 
of EGFP in the skin at the injection site and in a regional 
lymph node is shown.
The examples of the vaccination experiments performed with 
liposome formulations of antigen peptides and/or antigen encod-
ing DNA demonstrate that strong antigen-specific immune 
responses are obtained. Small unilamellar liposomes of the basic 
composition phosphatidylcholine and cholesterol have a signifi-
cant potential as delivery systems for the co-administration of 
peptide antigens and of immunostimulatory adjuvants, including 
CpG oligonucleotides, whereas the lipid composition POPC and 
DDAB was effective for the encapsulation of DNA encoding anti-
gens and/or immunostimulatory sequences. The liposome 
formulations have the advantage of ease of production at large 
scale, low costs of the components and proven safety. The results 
presented here clearly indicate that liposomal antigen delivery 
in vivo is a promising approach to induce efficient antiviral and 
anti-tumor immune responses with relevance for human applica-
tions. The process of RNA interference by short interfering RNA 
sequences (siRNA) represents a new class of molecules with a 
high potential for medical applications. Thus, the delivery of 
liposome encapsulated siRNA opens new opportunities for the 
development of novel antiviral and antitumor treatment modali-
ties for prophylaxis and treatment of virus infections and cancer in 
humans (27, 28). Furthermore, it appears likely that liposome 
based delivery systems modified by specific targeting functions to 
antigen presenting cells are well suited to further amplify the 
immune responses that mediate protection against viral infections 
or rapidly growing tumors.
 1. Cholesterol (e.g. from Fluka, purum quality, >95%) should 
be recrystallized from methanol. Cholesterol of minor quality 
should be avoided, since liposome membrane stability can be 
reduced. Store at 4°C, make a stock solution of 10 mg/mL 
by dissolving cholesterol in methanol.
 2. If the liposome vaccines are intended to be stored for longer 
periods of time, they may be frozen or lyophilized, provided 
4.  Conclusion
5.  Notes
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particles as a drug delivery system for peptides 
and proteins. Adv Drug Deliv Rev 59:478–490
 3. Kersten G, Hirschberg H (2004) Antigen deliv-
ery systems. Expert Rev Vaccines 3:453–462
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that they are prepared in a phosphate buffer that contains a 
cryoprotectant. We use an iso-osmolar phosphate-mannitol 
buffer of the following composition: 20 mM phosphate 
buffer (0.53 g/L KH2PO4 plus 2.87 g/L Na2HPO4⋅2H2O) 
plus 230 mM mannitol (42.0 g/L mannitol).
 3. The detachment of the lipid mixtures from the glass walls of 
the round bottom flasks can be accelerated by addition of 
small glass beads (2–3 mm diameter), followed by vigorous 
shaking. Preferably, the glass beads are added to the organic 
lipid solution before evaporation of the solvents. The encap-
sulation efficiency of hydrophilic molecules into the trapped 
volume of the liposomes is significantly increased by using the 
freeze–thaw method as described (29). Encapsulation effi-
ciency is further improved by performing the freeze–thaw 
cycles at high lipid per volume concentrations (e.g. 200 mg 
or more lipid/mL) as used in our studies. If synthetic lipids as 
liposome forming components are used, temperatures above 
the corresponding lipid transition temperature Tc have to be 
applied for the preparation process.
 4. If liquid nitrogen is not available, other freezing methods can 
be used, e.g. freezing the lipid suspension in a −80°C freezer 
or using other refrigerants like dry ice.
 5. Mean hydrodynamic diameters of vesicles (liposomes, 
nanospheres, nanobeads) can be determined by dynamic laser 
light scattering, e.g. the NICOMP 380 particle sizing instrument, 
Particle Sizing Systems (Sta. Barbara, CA, USA).
 6. Plasmid–DNA is trace labeled with 32P-DNA at a ratio of 
1,000 to 1 w/w. As an alternative, fluorescence labeled DNA 
can be used as trace label.
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